Estrella Immunopharma (Estrella Immunopharma) Accounts Payable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Accounts Payable?

Estrella Immunopharma's Accounts Payable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Estrella Immunopharma's quarterly Accounts Payable declined from Sep. 2023 ($9.34 Mil) to Dec. 2023 ($0.08 Mil) and declined from Dec. 2023 ($0.08 Mil) to Mar. 2024 ($0.00 Mil).

Estrella Immunopharma Accounts Payable Historical Data

The historical data trend for Estrella Immunopharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Accounts Payable Chart

Estrella Immunopharma Annual Data

Trend

Jun21

Accounts Payable

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial					4.31	-	9.34	0.08	-

Estrella Immunopharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Estrella Immunopharma Accounts Payable Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

ESLA:USA

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines